A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Evolve)

PHASE2CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

March 11, 2019

Primary Completion Date

July 15, 2020

Study Completion Date

August 12, 2020

Conditions
Acromegaly
Interventions
DRUG

Paltusotine

Paltusotine, capsules, once daily by mouth

DRUG

Placebo

Placebo, capsules, once daily by mouth

Trial Locations (11)

10260

The Research Institute of Dallas, Dallas

43210

Ohio State University, Columbus

Unknown

CETI - Centro de Estudos em Terapias Inovadoras, Curitiba

CPQuali Pesquisa Clinica, São Paulo

"General Hospital of Athens Gennimatas", Athens

Semmelweis University Faculty of Medicine, Budapest

University of Pécs Medical School, Pécs

Endocrine, Diabetes and Research Centre, Wellington Hospital, Wellington

The Centre of Postgraduate Medical Education, Warsaw

Clinical Centre Serbia, Clinic for Endocrinology, Diabetes and Metabolic Diseases, Belgrade

National Institute of Endocrinology and Diabetology, Ľubochňa

Sponsors
All Listed Sponsors
lead

Crinetics Pharmaceuticals Inc.

INDUSTRY

NCT03792555 - A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Evolve) | Biotech Hunter | Biotech Hunter